Long‐term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma

A 5‐year‐old boy with glioblastoma relapsed soon after postoperative irradiation in combination with temozolomide. Second‐line chemotherapy was also ineffective; therefore, the bevacizumab and irinotecan were given after a third gross‐total resection of the tumor. Treatment was interrupted for 1 mon...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics international 2015-02, Vol.57 (1), p.169-171
Main Authors: Umeda, Katsutsugu, Shibata, Hirofumi, Saida, Satoshi, Hiramatsu, Hidefumi, Arakawa, Yoshiki, Mizowaki, Takashi, Nishiuchi, Ritsuo, Adachi, Souichi, Heike, Toshio, Watanabe, Ken‐Ichiro
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - administration & dosage
Antineoplastic Agents, Phytogenic - administration & dosage
bevacizumab
Bevacizumab - administration & dosage
Brain cancer
Brain Neoplasms - diagnosis
Brain Neoplasms - drug therapy
Camptothecin - administration & dosage
Camptothecin - analogs & derivatives
Chemotherapy
Child, Preschool
Drug Therapy, Combination
Follow-Up Studies
glioblastoma
Glioblastoma - diagnosis
Glioblastoma - drug therapy
Humans
irinotecan
Magnetic Resonance Imaging
Male
Medical treatment
Neoplasm Recurrence, Local - drug therapy
Pediatrics
posterior reversible encephalopathy syndrome
Prodrugs
Time Factors
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 5‐year‐old boy with glioblastoma relapsed soon after postoperative irradiation in combination with temozolomide. Second‐line chemotherapy was also ineffective; therefore, the bevacizumab and irinotecan were given after a third gross‐total resection of the tumor. Treatment was interrupted for 1 month due to development of posterior reversible encephalopathy syndrome, but was re‐initiated at a lower dose of bevacizumab with prolonged intervals between treatments. The patient was alive and disease free 2 years after initial diagnosis. Bevacizumab and irinotecan are a promising regimen for pediatric cases of recurrent glioblastoma after gross‐total resection, although the optimal treatment schedule must be determined on a patient‐by‐patient basis.
ISSN:1328-8067
1442-200X
DOI:10.1111/ped.12414